Quarterly Activities/Appendix 4C Cash Flow Report

• Total sales for Q3 FY27 were US$6.3 million, a 30% increase from the previous corresponding period (PCP)
• Last twelve months (LTM) sales reached US$25.1 million, up 30% on the PCP
• Positive group cash flow from operations of A$0.5 million for the quarter, with A$4.1 million of liquidity on hand at 30 September 2026
• Sales and EBITDA guidance for FY27 confirmed
• Financial reporting in US$ will commence in H1 FY27

Nova EYE Medical Ltd, a medical technology company, reported its quarterly activities and cash flow for the three months ended 30 September 2026. The company reported total sales of US$6.3 million for the quarter, a 30% increase from the previous corresponding period (PCP). Last twelve months (LTM) sales reached US$25.1 million, up 30% on the PCP, showing an acceleration in the growth rate compared with sales for the twelve months to 30 June 2026. The company generated a positive group cash flow from operations of A$0.5 million for the quarter, with A$4.1 million of liquidity on hand at 30 September 2026 (Cash A$2.1 million and A$2.0 million of unused debt facility). Positive EBITDA for the quarter follows positive EBITDA reported for the six months ended 30 June 2026. Sales and EBITDA guidance for FY27 were confirmed. Financial reporting in US$ will commence in H1 FY27.

Sales, excluding China, are expected to be between US$26 million and US$31 million for FY27

Nova EYE Medical Ltd expects to continue its growth trajectory and achieve positive EBITDA for FY27. The company is actively engaged in negotiations with independent third parties to replace its existing unsecured facility agreement.